Whitney High
Concepts (371)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 15 | 2020 | 841 | 2.450 |
Why?
| Melanoma | 13 | 2020 | 709 | 2.430 |
Why?
| Skin Diseases | 10 | 2013 | 171 | 2.070 |
Why?
| Skin Diseases, Vesiculobullous | 4 | 2011 | 17 | 1.370 |
Why?
| Dermatology | 5 | 2013 | 204 | 1.240 |
Why?
| Immunohistochemistry | 14 | 2020 | 1727 | 1.190 |
Why?
| Nephrogenic Fibrosing Dermopathy | 6 | 2012 | 8 | 1.120 |
Why?
| Nevus, Pigmented | 4 | 2020 | 40 | 1.040 |
Why?
| Gadolinium DTPA | 6 | 2012 | 56 | 1.000 |
Why?
| Bedbugs | 2 | 2017 | 2 | 0.970 |
Why?
| Contrast Media | 9 | 2012 | 387 | 0.900 |
Why?
| Malpractice | 3 | 2013 | 42 | 0.860 |
Why?
| Skin | 11 | 2011 | 694 | 0.840 |
Why?
| Lupus Erythematosus, Cutaneous | 3 | 2007 | 7 | 0.820 |
Why?
| Gadolinium | 4 | 2010 | 78 | 0.810 |
Why?
| Dermatitis, Allergic Contact | 3 | 2006 | 62 | 0.720 |
Why?
| Psoriasis | 3 | 2013 | 86 | 0.660 |
Why?
| Kidney Failure, Chronic | 3 | 2009 | 519 | 0.650 |
Why?
| Skin Ulcer | 1 | 2018 | 17 | 0.640 |
Why?
| Seminoma | 1 | 2018 | 17 | 0.640 |
Why?
| Histiocytosis, Langerhans-Cell | 2 | 2008 | 36 | 0.630 |
Why?
| Ectoparasitic Infestations | 1 | 2017 | 3 | 0.610 |
Why?
| Neoplasms, Germ Cell and Embryonal | 1 | 2018 | 50 | 0.600 |
Why?
| Testicular Neoplasms | 1 | 2018 | 85 | 0.590 |
Why?
| Dermatitis, Atopic | 3 | 2013 | 342 | 0.560 |
Why?
| Erythema | 3 | 2009 | 26 | 0.560 |
Why?
| Scrotum | 2 | 2018 | 25 | 0.550 |
Why?
| Nail Diseases | 2 | 2006 | 5 | 0.540 |
Why?
| Fibrosis | 6 | 2008 | 497 | 0.510 |
Why?
| Humans | 68 | 2021 | 122796 | 0.500 |
Why?
| Medicare | 1 | 2020 | 767 | 0.490 |
Why?
| Neurothekeoma | 1 | 2014 | 4 | 0.490 |
Why?
| Defensive Medicine | 1 | 2013 | 2 | 0.490 |
Why?
| Telepathology | 1 | 2013 | 4 | 0.480 |
Why?
| Licensure | 1 | 2013 | 10 | 0.480 |
Why?
| Antibodies, Monoclonal | 3 | 2014 | 1306 | 0.470 |
Why?
| Diagnostic Errors | 2 | 2012 | 171 | 0.470 |
Why?
| Lupus Erythematosus, Discoid | 2 | 2015 | 7 | 0.410 |
Why?
| Scabies | 1 | 2011 | 2 | 0.410 |
Why?
| Elephantiasis | 1 | 2011 | 3 | 0.410 |
Why?
| Ganglion Cysts | 1 | 2011 | 10 | 0.400 |
Why?
| Genital Diseases, Male | 1 | 2011 | 16 | 0.400 |
Why?
| Acromioclavicular Joint | 1 | 2011 | 16 | 0.400 |
Why?
| Hidradenitis Suppurativa | 1 | 2011 | 15 | 0.400 |
Why?
| Male | 37 | 2020 | 59639 | 0.390 |
Why?
| Biopsy | 7 | 2021 | 1090 | 0.380 |
Why?
| Piperazines | 2 | 2012 | 326 | 0.370 |
Why?
| Insect Bites and Stings | 1 | 2009 | 11 | 0.360 |
Why?
| Pyrimidines | 2 | 2012 | 388 | 0.350 |
Why?
| Cocaine | 2 | 2012 | 157 | 0.350 |
Why?
| Diagnosis, Differential | 9 | 2015 | 1423 | 0.340 |
Why?
| Adult | 28 | 2020 | 32385 | 0.340 |
Why?
| Keratoacanthoma | 1 | 2008 | 3 | 0.340 |
Why?
| Keratolytic Agents | 1 | 2008 | 5 | 0.340 |
Why?
| Spectrometry, Fluorescence | 1 | 2009 | 171 | 0.340 |
Why?
| Biomarkers, Tumor | 4 | 2020 | 1076 | 0.340 |
Why?
| Isotretinoin | 1 | 2008 | 23 | 0.340 |
Why?
| Antineoplastic Agents | 3 | 2010 | 1990 | 0.340 |
Why?
| Female | 36 | 2020 | 63629 | 0.330 |
Why?
| Hypersensitivity, Delayed | 1 | 2008 | 52 | 0.330 |
Why?
| Pyroglyphidae | 1 | 2008 | 17 | 0.330 |
Why?
| Syphilis | 2 | 2005 | 37 | 0.320 |
Why?
| Pathology, Clinical | 1 | 2008 | 34 | 0.320 |
Why?
| Sweet Syndrome | 1 | 2007 | 7 | 0.320 |
Why?
| Scleroderma, Systemic | 1 | 2008 | 96 | 0.310 |
Why?
| Middle Aged | 23 | 2020 | 28563 | 0.310 |
Why?
| Aged | 20 | 2021 | 20495 | 0.300 |
Why?
| Dermatomyositis | 2 | 2004 | 22 | 0.300 |
Why?
| Alopecia | 2 | 2013 | 35 | 0.300 |
Why?
| Skin Diseases, Infectious | 1 | 2007 | 18 | 0.300 |
Why?
| Body Piercing | 1 | 2006 | 4 | 0.300 |
Why?
| Kidney Diseases | 2 | 2008 | 446 | 0.300 |
Why?
| Antibodies, Antinuclear | 2 | 2004 | 59 | 0.300 |
Why?
| Histiocytoma | 1 | 2006 | 2 | 0.290 |
Why?
| Hemangiopericytoma | 1 | 2006 | 3 | 0.290 |
Why?
| Neoplastic Syndromes, Hereditary | 1 | 2007 | 29 | 0.290 |
Why?
| Epithelioid Cells | 1 | 2006 | 8 | 0.290 |
Why?
| Communicable Diseases, Emerging | 1 | 2007 | 28 | 0.290 |
Why?
| Granuloma, Pyogenic | 1 | 2006 | 6 | 0.290 |
Why?
| Lymphoma, T-Cell, Cutaneous | 1 | 2007 | 42 | 0.290 |
Why?
| Dermatitis, Seborrheic | 1 | 2006 | 6 | 0.290 |
Why?
| Titanium | 1 | 2006 | 64 | 0.280 |
Why?
| Granuloma | 1 | 2006 | 93 | 0.280 |
Why?
| Exanthema | 1 | 2007 | 78 | 0.280 |
Why?
| Epstein-Barr Virus Infections | 1 | 2007 | 73 | 0.270 |
Why?
| Hyperkeratosis, Epidermolytic | 1 | 2005 | 20 | 0.270 |
Why?
| Neoplasm Regression, Spontaneous | 1 | 2005 | 3 | 0.270 |
Why?
| Genital Diseases, Female | 1 | 2005 | 29 | 0.270 |
Why?
| Scalp | 1 | 2005 | 29 | 0.270 |
Why?
| Tacrolimus | 1 | 2006 | 154 | 0.260 |
Why?
| Telemedicine | 1 | 2013 | 691 | 0.260 |
Why?
| Ear, External | 1 | 2004 | 26 | 0.260 |
Why?
| Ossification, Heterotopic | 1 | 2004 | 16 | 0.260 |
Why?
| Ear Diseases | 1 | 2004 | 15 | 0.260 |
Why?
| Quinazolines | 1 | 2006 | 243 | 0.250 |
Why?
| Tuberculosis, Miliary | 1 | 2004 | 5 | 0.250 |
Why?
| Tuberculosis, Cutaneous | 1 | 2004 | 4 | 0.250 |
Why?
| Allergens | 1 | 2008 | 421 | 0.250 |
Why?
| Agave | 1 | 2003 | 1 | 0.240 |
Why?
| Fibroma | 1 | 2004 | 20 | 0.240 |
Why?
| Biopsy, Needle | 5 | 2011 | 192 | 0.240 |
Why?
| Alendronate | 1 | 2003 | 7 | 0.230 |
Why?
| Tumor Virus Infections | 1 | 2003 | 41 | 0.230 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 302 | 0.230 |
Why?
| Protein Kinase Inhibitors | 2 | 2012 | 833 | 0.230 |
Why?
| AIDS-Related Opportunistic Infections | 1 | 2004 | 114 | 0.230 |
Why?
| Carcinoma, Squamous Cell | 3 | 2010 | 622 | 0.230 |
Why?
| Facial Dermatoses | 1 | 2003 | 16 | 0.230 |
Why?
| Women's Health | 1 | 2005 | 277 | 0.230 |
Why?
| Hyperpigmentation | 1 | 2003 | 12 | 0.230 |
Why?
| Neoplasm Invasiveness | 2 | 2020 | 472 | 0.230 |
Why?
| Vasculitis | 1 | 2003 | 75 | 0.230 |
Why?
| Papillomaviridae | 1 | 2003 | 102 | 0.230 |
Why?
| Lymphatic Metastasis | 2 | 2019 | 310 | 0.220 |
Why?
| Cicatrix | 1 | 2003 | 54 | 0.220 |
Why?
| Pregnancy Outcome | 1 | 2005 | 364 | 0.220 |
Why?
| Antirheumatic Agents | 1 | 2005 | 254 | 0.220 |
Why?
| United States | 7 | 2020 | 13272 | 0.220 |
Why?
| Prognosis | 5 | 2017 | 3563 | 0.210 |
Why?
| Cheilitis | 1 | 2021 | 3 | 0.210 |
Why?
| Patch Tests | 3 | 2008 | 50 | 0.200 |
Why?
| Pulmonary Fibrosis | 1 | 2003 | 305 | 0.190 |
Why?
| MART-1 Antigen | 1 | 2020 | 9 | 0.190 |
Why?
| Cannabis | 1 | 2007 | 389 | 0.190 |
Why?
| Genetic Testing | 2 | 2017 | 400 | 0.190 |
Why?
| Pregnancy Complications | 1 | 2005 | 462 | 0.190 |
Why?
| SOXE Transcription Factors | 1 | 2020 | 21 | 0.180 |
Why?
| Papillomavirus Infections | 1 | 2003 | 267 | 0.180 |
Why?
| Benzamides | 2 | 2012 | 175 | 0.180 |
Why?
| Aged, 80 and over | 8 | 2015 | 6845 | 0.180 |
Why?
| Societies, Medical | 1 | 2003 | 741 | 0.180 |
Why?
| HIV Infections | 2 | 2004 | 2532 | 0.170 |
Why?
| Head and Neck Neoplasms | 2 | 2019 | 475 | 0.170 |
Why?
| Retrospective Studies | 8 | 2020 | 13433 | 0.170 |
Why?
| Gene Regulatory Networks | 1 | 2020 | 244 | 0.170 |
Why?
| Methotrexate | 3 | 2012 | 227 | 0.160 |
Why?
| Dermoscopy | 2 | 2017 | 13 | 0.160 |
Why?
| Comparative Genomic Hybridization | 1 | 2017 | 28 | 0.160 |
Why?
| Lip | 2 | 2021 | 22 | 0.150 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2019 | 306 | 0.150 |
Why?
| Pruritus | 2 | 2009 | 62 | 0.150 |
Why?
| STAT3 Transcription Factor | 1 | 2019 | 193 | 0.150 |
Why?
| Bites and Stings | 1 | 2017 | 32 | 0.150 |
Why?
| Tumor Suppressor Proteins | 1 | 2019 | 299 | 0.150 |
Why?
| Severity of Illness Index | 4 | 2009 | 2784 | 0.140 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2017 | 319 | 0.140 |
Why?
| Lichenoid Eruptions | 1 | 2015 | 3 | 0.140 |
Why?
| Risk Assessment | 5 | 2011 | 3213 | 0.140 |
Why?
| Dermatologic Agents | 2 | 2013 | 64 | 0.140 |
Why?
| Mutation | 1 | 2007 | 3493 | 0.140 |
Why?
| Sampling Studies | 2 | 2007 | 95 | 0.140 |
Why?
| Magnetic Resonance Imaging | 4 | 2011 | 3264 | 0.130 |
Why?
| Child, Preschool | 4 | 2014 | 9755 | 0.130 |
Why?
| Child | 6 | 2014 | 19561 | 0.130 |
Why?
| Renal Dialysis | 2 | 2009 | 395 | 0.130 |
Why?
| Follow-Up Studies | 4 | 2011 | 4768 | 0.130 |
Why?
| Mass Spectrometry | 2 | 2008 | 686 | 0.120 |
Why?
| Insurance, Liability | 1 | 2013 | 7 | 0.120 |
Why?
| Face | 1 | 2015 | 179 | 0.120 |
Why?
| Mohs Surgery | 2 | 2004 | 29 | 0.120 |
Why?
| Animals | 8 | 2019 | 34133 | 0.120 |
Why?
| Liability, Legal | 1 | 2013 | 45 | 0.120 |
Why?
| Internship and Residency | 1 | 2003 | 1065 | 0.120 |
Why?
| Gene Expression Profiling | 1 | 2020 | 1625 | 0.110 |
Why?
| Photography | 1 | 2013 | 96 | 0.110 |
Why?
| Antinematodal Agents | 1 | 2012 | 5 | 0.110 |
Why?
| Imatinib Mesylate | 2 | 2012 | 63 | 0.110 |
Why?
| Immunosuppressive Agents | 2 | 2009 | 687 | 0.110 |
Why?
| Fetal Diseases | 1 | 2013 | 149 | 0.110 |
Why?
| Levamisole | 1 | 2012 | 19 | 0.110 |
Why?
| Drug Contamination | 1 | 2012 | 60 | 0.110 |
Why?
| Granulomatosis with Polyangiitis | 1 | 2012 | 41 | 0.110 |
Why?
| Argyria | 1 | 2011 | 4 | 0.100 |
Why?
| Orphanages | 1 | 2011 | 2 | 0.100 |
Why?
| Carcinoma, Basal Cell | 2 | 2010 | 77 | 0.100 |
Why?
| Granuloma, Foreign-Body | 1 | 2011 | 11 | 0.100 |
Why?
| Vietnam | 1 | 2011 | 23 | 0.100 |
Why?
| Ethiopia | 1 | 2011 | 36 | 0.100 |
Why?
| Pilot Projects | 2 | 2006 | 1477 | 0.100 |
Why?
| Durapatite | 1 | 2011 | 35 | 0.100 |
Why?
| Synovial Fluid | 1 | 2011 | 57 | 0.100 |
Why?
| Foreign-Body Migration | 1 | 2011 | 39 | 0.100 |
Why?
| Adoption | 1 | 2011 | 38 | 0.100 |
Why?
| Cocaine-Related Disorders | 1 | 2012 | 110 | 0.100 |
Why?
| Mucins | 1 | 2011 | 64 | 0.100 |
Why?
| Rupture | 1 | 2011 | 107 | 0.100 |
Why?
| Sensitivity and Specificity | 3 | 2020 | 1855 | 0.100 |
Why?
| Rotator Cuff Injuries | 1 | 2011 | 59 | 0.100 |
Why?
| Transcription Factors | 1 | 2019 | 1616 | 0.100 |
Why?
| Treatment Outcome | 4 | 2012 | 9692 | 0.100 |
Why?
| China | 1 | 2011 | 223 | 0.100 |
Why?
| Aminolevulinic Acid | 1 | 2010 | 3 | 0.090 |
Why?
| Adolescent | 5 | 2014 | 18948 | 0.090 |
Why?
| Injections, Intralesional | 1 | 2010 | 37 | 0.090 |
Why?
| Cell Differentiation | 1 | 2018 | 1805 | 0.090 |
Why?
| Eccrine Glands | 1 | 2009 | 2 | 0.090 |
Why?
| Synchrotrons | 1 | 2009 | 9 | 0.090 |
Why?
| Health Care Costs | 1 | 2013 | 414 | 0.090 |
Why?
| Guatemala | 1 | 2011 | 311 | 0.090 |
Why?
| Photopheresis | 1 | 2009 | 9 | 0.090 |
Why?
| Iron-Dextran Complex | 1 | 2009 | 10 | 0.090 |
Why?
| Practice Guidelines as Topic | 2 | 2008 | 1519 | 0.090 |
Why?
| Plasmapheresis | 1 | 2009 | 24 | 0.090 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 86 | 0.090 |
Why?
| Arthropod Vectors | 1 | 2009 | 7 | 0.090 |
Why?
| Ultraviolet Therapy | 1 | 2009 | 20 | 0.090 |
Why?
| Bedding and Linens | 1 | 2009 | 10 | 0.090 |
Why?
| Algorithms | 1 | 2017 | 1593 | 0.090 |
Why?
| Observation | 1 | 2009 | 55 | 0.090 |
Why?
| Hyaluronic Acid | 1 | 2011 | 203 | 0.090 |
Why?
| Naphthoquinones | 1 | 2009 | 18 | 0.090 |
Why?
| Fluorouracil | 1 | 2010 | 160 | 0.090 |
Why?
| Rituximab | 1 | 2010 | 161 | 0.090 |
Why?
| Lymphoma, B-Cell | 1 | 2010 | 90 | 0.090 |
Why?
| Erythropoietin | 1 | 2009 | 82 | 0.090 |
Why?
| Interferon-alpha | 1 | 2010 | 190 | 0.080 |
Why?
| Interleukin-2 | 1 | 2010 | 420 | 0.080 |
Why?
| Bleomycin | 1 | 2010 | 217 | 0.080 |
Why?
| Histiocytes | 1 | 2008 | 5 | 0.080 |
Why?
| Langerhans Cells | 1 | 2008 | 11 | 0.080 |
Why?
| Histiocytosis | 1 | 2008 | 8 | 0.080 |
Why?
| Diabetes Insipidus | 1 | 2008 | 8 | 0.080 |
Why?
| Vitiligo | 1 | 2009 | 77 | 0.080 |
Why?
| Carcinoma, Skin Appendage | 1 | 2007 | 2 | 0.080 |
Why?
| Failure to Thrive | 1 | 2008 | 30 | 0.080 |
Why?
| Prednisone | 2 | 2012 | 234 | 0.080 |
Why?
| Antigen-Presenting Cells | 1 | 2008 | 157 | 0.080 |
Why?
| Imidazoles | 1 | 2009 | 234 | 0.080 |
Why?
| Neoplasm Metastasis | 1 | 2010 | 563 | 0.080 |
Why?
| Microtubule-Associated Proteins | 1 | 2009 | 187 | 0.080 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 2008 | 133 | 0.080 |
Why?
| Medical Records | 1 | 2008 | 181 | 0.080 |
Why?
| Bone Diseases | 1 | 2008 | 60 | 0.080 |
Why?
| Risk Management | 1 | 2008 | 94 | 0.080 |
Why?
| Amoeba | 1 | 2007 | 1 | 0.080 |
Why?
| Gnathostoma | 1 | 2007 | 1 | 0.080 |
Why?
| Pythium | 1 | 2007 | 1 | 0.080 |
Why?
| Spirurida Infections | 1 | 2007 | 1 | 0.080 |
Why?
| Amebiasis | 1 | 2007 | 5 | 0.080 |
Why?
| Penicillium | 1 | 2007 | 6 | 0.080 |
Why?
| Genes, p16 | 1 | 2007 | 19 | 0.070 |
Why?
| Electron Probe Microanalysis | 1 | 2006 | 3 | 0.070 |
Why?
| Case-Control Studies | 2 | 2020 | 3296 | 0.070 |
Why?
| Microphthalmia-Associated Transcription Factor | 1 | 2007 | 15 | 0.070 |
Why?
| Keratinocytes | 1 | 2008 | 238 | 0.070 |
Why?
| Receptor, Melanocortin, Type 1 | 1 | 2007 | 26 | 0.070 |
Why?
| Pregnancy | 3 | 2013 | 5854 | 0.070 |
Why?
| Paraffin Embedding | 1 | 2006 | 23 | 0.070 |
Why?
| Epidermis | 1 | 2007 | 152 | 0.070 |
Why?
| Factor XIIIa | 1 | 2006 | 5 | 0.070 |
Why?
| Skull | 1 | 2008 | 145 | 0.070 |
Why?
| Subcutaneous Tissue | 1 | 2006 | 20 | 0.070 |
Why?
| Dermis | 1 | 2006 | 30 | 0.070 |
Why?
| Dosage Forms | 1 | 2006 | 11 | 0.070 |
Why?
| Hypopigmentation | 1 | 2006 | 3 | 0.070 |
Why?
| Neoplasms, Unknown Primary | 1 | 2006 | 12 | 0.070 |
Why?
| Microscopy, Electron, Scanning | 1 | 2006 | 201 | 0.070 |
Why?
| Combined Modality Therapy | 1 | 2009 | 1174 | 0.070 |
Why?
| Diabetic Nephropathies | 1 | 2009 | 292 | 0.070 |
Why?
| Lysosomes | 1 | 2006 | 136 | 0.070 |
Why?
| Organ Specificity | 1 | 2006 | 287 | 0.070 |
Why?
| Single-Blind Method | 1 | 2006 | 275 | 0.070 |
Why?
| Metals | 1 | 2006 | 116 | 0.070 |
Why?
| Tissue Distribution | 1 | 2006 | 339 | 0.070 |
Why?
| PTEN Phosphohydrolase | 1 | 2007 | 149 | 0.070 |
Why?
| Viscera | 1 | 2005 | 16 | 0.070 |
Why?
| Acidosis | 1 | 2006 | 94 | 0.070 |
Why?
| Pregnancy, Multiple | 1 | 2005 | 20 | 0.070 |
Why?
| Remission, Spontaneous | 1 | 2005 | 37 | 0.070 |
Why?
| Mitosis | 1 | 2006 | 175 | 0.070 |
Why?
| Signal Transduction | 1 | 2019 | 4902 | 0.070 |
Why?
| Pregnancy Trimester, Third | 1 | 2005 | 73 | 0.070 |
Why?
| Radiography | 1 | 2008 | 888 | 0.070 |
Why?
| Knee Joint | 1 | 2008 | 366 | 0.060 |
Why?
| Iron | 1 | 2006 | 239 | 0.060 |
Why?
| Infliximab | 1 | 2005 | 95 | 0.060 |
Why?
| Rare Diseases | 1 | 2005 | 116 | 0.060 |
Why?
| Treponema pallidum | 1 | 2004 | 13 | 0.060 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2007 | 204 | 0.060 |
Why?
| Foot | 1 | 2005 | 125 | 0.060 |
Why?
| Urticaria | 1 | 2005 | 52 | 0.060 |
Why?
| Renal Insufficiency | 1 | 2006 | 154 | 0.060 |
Why?
| Sclerosis | 1 | 2004 | 14 | 0.060 |
Why?
| Hand | 1 | 2005 | 139 | 0.060 |
Why?
| Cell Transformation, Neoplastic | 1 | 2007 | 320 | 0.060 |
Why?
| Infant, Newborn | 2 | 2007 | 5430 | 0.060 |
Why?
| Glucocorticoids | 2 | 2012 | 554 | 0.060 |
Why?
| Infant | 2 | 2008 | 8523 | 0.060 |
Why?
| Infusions, Intravenous | 1 | 2005 | 396 | 0.060 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 1183 | 0.060 |
Why?
| Kidney Transplantation | 1 | 2010 | 584 | 0.060 |
Why?
| Nails | 1 | 2003 | 10 | 0.060 |
Why?
| Staining and Labeling | 1 | 2004 | 159 | 0.060 |
Why?
| Twins | 1 | 2005 | 247 | 0.060 |
Why?
| Chest Pain | 1 | 2004 | 94 | 0.060 |
Why?
| Cell Nucleus | 1 | 2006 | 598 | 0.060 |
Why?
| Quality of Health Care | 1 | 2008 | 631 | 0.060 |
Why?
| Arm | 1 | 2003 | 107 | 0.060 |
Why?
| Renal Insufficiency, Chronic | 1 | 2009 | 602 | 0.060 |
Why?
| Plant Leaves | 1 | 2003 | 120 | 0.060 |
Why?
| Cell Cycle Proteins | 1 | 2007 | 576 | 0.060 |
Why?
| Atrophy | 1 | 2003 | 167 | 0.050 |
Why?
| Fatal Outcome | 1 | 2003 | 299 | 0.050 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2006 | 466 | 0.050 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 839 | 0.050 |
Why?
| Young Adult | 2 | 2015 | 11094 | 0.050 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2004 | 235 | 0.050 |
Why?
| Adrenal Cortex Hormones | 1 | 2005 | 515 | 0.050 |
Why?
| Plasma Cells | 1 | 2021 | 60 | 0.050 |
Why?
| Coronary Disease | 1 | 2004 | 372 | 0.050 |
Why?
| Blotting, Western | 1 | 2004 | 1225 | 0.050 |
Why?
| Neoplasm Staging | 1 | 2004 | 1234 | 0.050 |
Why?
| Age Factors | 1 | 2008 | 3114 | 0.050 |
Why?
| Cohort Studies | 2 | 2008 | 5294 | 0.050 |
Why?
| Osteoporosis | 1 | 2003 | 234 | 0.050 |
Why?
| Rats, Wistar | 2 | 2012 | 405 | 0.050 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1402 | 0.050 |
Why?
| Respiratory Insufficiency | 1 | 2003 | 305 | 0.040 |
Why?
| Kidney | 1 | 2007 | 1355 | 0.040 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 967 | 0.040 |
Why?
| Genotype | 1 | 2003 | 1943 | 0.040 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 1003 | 0.040 |
Why?
| Genetic Predisposition to Disease | 1 | 2007 | 2359 | 0.040 |
Why?
| Risk Factors | 2 | 2009 | 9381 | 0.040 |
Why?
| Carcinogenesis | 1 | 2019 | 184 | 0.040 |
Why?
| Mice, Nude | 1 | 2019 | 668 | 0.040 |
Why?
| Arthritis, Rheumatoid | 1 | 2005 | 985 | 0.040 |
Why?
| Clinical Competence | 1 | 2003 | 973 | 0.040 |
Why?
| Early Detection of Cancer | 1 | 2020 | 364 | 0.030 |
Why?
| Clinical Decision-Making | 1 | 2017 | 293 | 0.030 |
Why?
| Minoxidil | 1 | 2013 | 1 | 0.030 |
Why?
| Retinoids | 1 | 2013 | 35 | 0.030 |
Why?
| Acne Vulgaris | 1 | 2013 | 28 | 0.030 |
Why?
| Hydroxychloroquine | 1 | 2013 | 58 | 0.030 |
Why?
| Lung Neoplasms | 1 | 2006 | 2216 | 0.030 |
Why?
| Inflammation | 1 | 2004 | 2598 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2003 | 4734 | 0.030 |
Why?
| Emergency Service, Hospital | 1 | 2004 | 1922 | 0.030 |
Why?
| Rats | 2 | 2012 | 5426 | 0.030 |
Why?
| Injections, Intradermal | 1 | 2011 | 11 | 0.030 |
Why?
| Cell Line, Tumor | 1 | 2019 | 2904 | 0.030 |
Why?
| Disease Progression | 1 | 2019 | 2546 | 0.030 |
Why?
| Transcriptome | 1 | 2017 | 774 | 0.030 |
Why?
| Surveys and Questionnaires | 1 | 2003 | 4882 | 0.030 |
Why?
| Cosmetic Techniques | 1 | 2011 | 18 | 0.030 |
Why?
| Microscopy, Electron | 1 | 2011 | 418 | 0.020 |
Why?
| Epoetin Alfa | 1 | 2009 | 6 | 0.020 |
Why?
| Injections, Intravenous | 1 | 2009 | 217 | 0.020 |
Why?
| Drug Therapy, Combination | 1 | 2012 | 988 | 0.020 |
Why?
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 44 | 0.020 |
Why?
| Drug Synergism | 1 | 2009 | 346 | 0.020 |
Why?
| Keratin-15 | 1 | 2007 | 14 | 0.020 |
Why?
| Remission Induction | 1 | 2008 | 246 | 0.020 |
Why?
| Axilla | 1 | 2006 | 58 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2009 | 1184 | 0.020 |
Why?
| Recombinant Proteins | 1 | 2009 | 1318 | 0.020 |
Why?
| Silver Staining | 1 | 2004 | 19 | 0.020 |
Why?
| Databases, Factual | 1 | 2010 | 1287 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2009 | 1981 | 0.020 |
Why?
| Echocardiography, Stress | 1 | 2004 | 27 | 0.020 |
Why?
| Incidence | 1 | 2010 | 2527 | 0.010 |
Why?
| Causality | 1 | 2004 | 115 | 0.010 |
Why?
| Calcium | 1 | 2009 | 1244 | 0.010 |
Why?
| Mice | 1 | 2019 | 15888 | 0.010 |
Why?
| Gastrointestinal Diseases | 1 | 2004 | 195 | 0.010 |
Why?
| Electroencephalography | 1 | 2004 | 408 | 0.010 |
Why?
| Acute Disease | 1 | 2004 | 984 | 0.010 |
Why?
| Exercise Test | 1 | 2004 | 588 | 0.010 |
Why?
| Recurrence | 1 | 2004 | 998 | 0.010 |
Why?
| Survival Analysis | 1 | 2004 | 1325 | 0.010 |
Why?
| Hospitalization | 1 | 2004 | 1914 | 0.010 |
Why?
|
|
High's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|